Investor Presentaiton
R&D investor presentation
Acquisition of Corvidia Therapeutics supports Novo Nordisk's
ambition within cardiovascular disease
27
22
C
CORVIDIA
Precision Cardiovascular Therapeutics
Boston, USA, based company
focused on R&D and
commercialisation of transformative
medicines for life threatening
diseases
Lead compound "Ziltivekimab", an
anti-IL-6 monoclonal antibody, to
reduce cardiovascular risk in
atherosclerotic CVD with chronic
kidney disease and inflammation,
currently in phase 2 development
Population: Estimated 5 million
patients with ASCVD have CKD and
inflammation with no approved
therapies
Target: IL-6 axis is shown to be a
central mediator of inflammatory
cardiovascular risk, and specifically in
CKD patients correlating with high CV
event rates
Compound: Advanced fully human
anti-IL6 ligand mAb with potential for
optimal dosing to maximize efficacy-
safety profile compared to existing
anti-IL6
ASCVD: atherosclerotic cardiovascular disease; mAb: monoclonal antibody; CKD: chronic kidney disease; CVD:
cardiovascular disease
Differentiation: Ziltivekimab has
potential to become first-in-class and
best in class product in a patient
population with limited treatments
options availableView entire presentation